Clinical trials: Leishmaniasis, Cutaneous
Cutaneous Leishmaniasis
Oral Miltefosine Plus Topical Imiquimod to Treat Cutaneous Leishmaniasis
Cutaneous leishmaniasis is endemic in the New World from approximately the US-Mexican border through Central America and the Northern part of South America down to the level of Rio de Janeiro.
- Trial name
- NCT01380314
- Testing
- Miltefosine + Imiquimod
- Where
- Bolivia
- Volunteers
- 60 people
- Sponsor
- Foundation Fader
Cutaneous Leishmaniasis
Epidemiology of Cutaneous Leishmaniasis in Niger, Mali, Togo : Mapping of Clinical Cases, Species, Reservoirs and Vectors of the Disease
Cutaneous leishmaniasis is a neglected tropical disease caused by parasites belonging to the genus Leishmania. This infection can cause skin and sometimes mucous membrane lesions with significant damage.
- Trial name
- LEISHAFRICA (NCT06692985)
- Testing
- Clinical and epidemiological data, Parasitological samples, Assessment of clinical course and response to treatment
- Where
- 3 sites in Mali, Niger and 1 more
- Volunteers
- 270 people
- Sponsor
- Centre Hospitalier de Cayenne
Cutaneous Leishmaniasis
Imiquimod Plus Antimony Immunochemotherapy for Cutaneous Leishmaniasis
This study will test whether addition of imiquimod to standard antimony therapy provides a significant benefit in subjects with newly diagnosed cutaneous leishmaniasis.
- Trial name
- NCT00257530
- Testing
- Imiquimod
- Where
- 2 sites in Peru
- Volunteers
- 80 people
- Sponsor
- Drugs for Neglected Diseases
Treatment of Cutaneous Leishmaniasis in Brazil.
Trial of Miltefosine in Cutaneous Leishmaniasis (Brazil)
The hypothesis of this trial is that the therapeutic activity and safety of oral miltefosine in Brazilian patients with cutaneous leishmaniasis is similar or superior to the intravenous standard treatment (meglumine antimoniate …
- Trial name
- NCT00600548
- Testing
- Miltefosine., Meglumine antimoniate.
- Where
- 2 sites in Brazil
- Volunteers
- 180 people
- Sponsor
- Hospital Universitário Professor Edgard Santos
Wound Healing
Rationales for Wound Care Management in Old World Cutaneous Leishmaniasis Patients
The rationales of a clinical trial comparing intralesional antimonial therapy versus wound care management in patients with old world cutaneous leishmaniasis (OWCL) are the following: 1.
- Trial name
- LEICO (NCT00996463)
- Testing
- Electro-thermo-coagulation, Sodium Stibogluconate, DAC N-055
- Where
- Afghanistan
- Volunteers
- 63 people
- Sponsor
- Waisenmedizin e. V. Promoting Access to Essential Medicine
Cutaneous Leishmaniasis, Cutaneous Leishmaniasis, American
Pilot Study: Miltefosine Gel (G-MTF) in Patients With Cutaneous Leishmaniasis
The goal of this clinical trial is to learn if the drug MILTEFOSINE, used topically in a hydrogel, works to treat non-complicated cutaneous leishmaniasis (CL) in adults.
- Conditions
- Cutaneous Leishmaniasis, Cutaneous Leishmaniasis, American, Topical Administration
- Trial name
- G-MTF01 (NCT07149753)
- Testing
- MILTEFOSINE gel
- Where
- Colombia
- Volunteers
- 15 people
- Sponsor
- Universidad Industrial de Santander
Cutaneous Leishmaniasis (Diagnosis)
Performance of RPA-LF for Cutaneous Leishmaniasis
CL is public health in the Americas, diagnostic confirmation is required to start treatment, however current diagnostic methods have several limitations and its access is limited.
- Trial name
- RPA-LF (NCT04500873)
- Where
- Colombia
- Volunteers
- 128 people
- Sponsor
- Centro Internacional de Entrenamiento e Investigaciones Médicas
Leishmaniasis
The Association of Miltefosine and Pentoxifylline to Treat Mucosal and Cutaneous Leishmaniasis: A Clinical Trial in Brazil
Mucocutaneous leishmaniasis is endemic in the central region of Brazil and other countries worldwide. The standard treatment with meglumine antimoniate has a high rate of important adverse effects.
- Trial name
- NCT02530697
- Testing
- Meglumine antimoniate, Miltefosine, Pentoxifylline
- Where
- Brazil
- Volunteers
- 160 people
- Sponsor
- University of Brasilia
Leishmaniasis, Cutaneous, Insect Bites
A Clinical Study to Develop an Uninfected Sand Fly Biting Protocol
The disease leishmaniasis mainly occurs in hot and tropical countries, affects millions of people and causes around 20,000 deaths across the world every year.
- Trial name
- FLYBITE (NCT03999970)
- Testing
- Sand fly bite
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of York
Cutaneous Leishmaniases
Outcomes of Complicated CL in Ethiopia Treated With Miltefosine
Cutaneous Leishmaniasis in Ethiopia causes severe dermatological mutilations. Forms that require systemic treatment are cLCL, MCL, and DCL. National guidelines recommend equally all drugs that are also used for VL treatment.
- Trial name
- NCT04004754
- Testing
- Miltefosine (administration is not part of study procedures)
- Where
- 2 sites in Ethiopia
- Volunteers
- 94 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Cutaneous Leishmaniasis
Prospective Observational Study of Intralesional Treatment With Pentostam in Cutaneous Leishmaniasis Israeli Patients
Cutaneous leishmaniasis (CL) is endemic in Israel and is caused by Leishmania major or Leishmania tropica. CL is usually a benign disease and limited to the skin.
- Trial name
- NCT02281669
- Testing
- Pentostam
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Sheba Medical Center
Leishmaniasis
Allopurinol, Glucantime, or Allopurinol/Glucantime for Cutaneous Leishmaniasis in Brazil
OBJECTIVE: Compare the efficacy and side effects of allopurinol versus glucantime versus allopurinol/glucantime in patients in Brazil with cutaneous leishmaniasis.
- Trial name
- NCT00004755
- Testing
- allopurinol, glucantime
- Volunteers
- 375 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cutaneous Leishmaniasis
Intralesional Injection of Levofloxacin for the Management of Cutaneous Leishmaniasis
Aim of the study to evaluate the effectiveness of intralesional levofloxacin 0.5% solution as a local injection in treating cutaneous leishmaniasis.
- Trial name
- NCT06797544
- Testing
- Levofloxacin 0.5%
- Where
- Iraq
- Volunteers
- 40 people
- Sponsor
- Hayder Adnan Fawzi
Leishmaniasis, Cutaneous Leishmaniasis
Intralesional Antimony for Bolivian Cutaneous Leishmaniasis
Intralesional injection of antimony has been used for L major from Iran with a modest cure rate [56%: Asilian 2004]. However, this therapeutic approach has been used for L braziliensis from Brazil, with an attractive cure rate…
- Trial name
- NCT01300975
- Testing
- pentavalent antimony, cryotherapy
- Where
- 2 sites in Bolivia
- Volunteers
- 90 people
- Sponsor
- Fundacion Nacional de Dermatologia
Cutaneous Leishmaniasis, Scar
Cosmetic Outcome of Leishmaniasis Scar After WR279396 Application
Primary Objectives: Assess whether CL (caused by Leishmaniasis major) lesions treated with WR279396 improved the cosmetic outcome compared with no treatment (natural healing)
- Trial name
- SCAR (NCT00490230)
- Testing
- WR 279396
- Where
- Tunisia
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Visceral Leishmaniasis, Cutaneous Leishmaniases
Single Oral Dose Escalation Study of DNDI-0690 in Healthy Subjects
This study will evaluate how the test medicine DNDI-0690 is taken up and broken down by the body and will also look at the safety and tolerability of the test medicine after a single dose.
- Trial name
- NCT03929016
- Testing
- DNDI-0690
- Where
- United Kingdom
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Drugs for Neglected Diseases
Cutaneous Leishmaniasis
Oral Miltefosine for the Treatment of Pediatric Cutaneous Leishmaniasis in Colombia
The purpose of this randomized, open label clinical trial is to determine if oral miltefosine is a safe and effective alternative, compared with parenteral meglumine antimoniate for the treatment of pediatric Cutaneous caused by…
- Trial name
- NCT00487253
- Testing
- Miltefosine, Meglumine antimoniate
- Volunteers
- 150 people
- Sponsor
- Centro Internacional de Entrenamiento e Investigaciones Médicas
Mucosal Leishmaniasis
Treatment of Mucosal Bolivian Leishmaniasis
The purpose of this protocol is to conduct a randomized comparison of the efficacy and tolerance of miltefosine, LAMB, and pentavalent antimony for the treatment of mucosal leishmaniasis.
- Trial name
- NCT04799236
- Testing
- Group 1: Miltefosine, Group 2: Pentavalent Antimony, Group 3: Liposomal amphotericin B
- Where
- Bolivia
- Volunteers
- 120 people
- Sponsor
- Fundacion Nacional de Dermatologia
Post-kala-azar Dermal Leishmaniasis
A Study to Explore Association of Treatment Regimens for Visceral Leishmaniasis, Host Immunological, Genetical and Nutrition Factors With Post-kala-azar Dermal Leishmaniasis (PKDL)
We hypothesize that PKDL develop after SSG as well as after Miltefosine mono-therapy for VL; anti-inflammatory cytokines such as IL-10, TGF-β, serum lipids play key role for its pathogenesis \& PKDL patients are genetically…
- Trial name
- NCT01975051
- Testing
- Mitefosine
- Where
- Bangladesh
- Volunteers
- 36 people
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
Visceral Leishmaniasis, Post-kala-azar Dermal Leishmaniasis
Open-Label Safety Study of Three-Antigen Leishmania Polyprotein With Adjuvant MPL-SE in Healthy Adults in India
The purpose of this study is to determine if a vaccine (called Leish-111f + MPL-SE) is safe and whether it can or cannot produce a protective response against visceral leishmaniasis when injected to healthy subjects.
- Trial name
- NCT00486382
- Testing
- Leish-111f + MPL-SE Adjuvant
- Where
- India
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Access to Advanced Health Institute (AAHI)